Navigation Links
Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
Date:3/12/2008

WILMINGTON, Del., March 12, 2008 AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the companys investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.

ZODIAC is a randomized, double-blind, international, multi-center Phase III study to assess the efficacy of vandetanib 100mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of first-line anti-cancer therapy.

ZEAL is a Phase III parallel group, randomized, double-blind study evaluating vandetanib 100mg once daily plus pemetrexed 500mg/m2 (every 3 weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

The ZEST study, which is investigating vandetanib versus erlotinib, was the first Phase III study of vandetanib to complete enrollment in November 2007.

NSCLC is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer, said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZODIAC and ZEAL are part of a broad Phase III clinical trial program designed to gain an understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

  • ZEST (vandetanib versus erlotinib) enrollment is complete; and
  • ZEPHYR (vandetanib + best supportive care (BSC) versus BSC).

The ZEPHYR study is currently recruiting patients.

The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel). Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this tumor type.


'/>"/>

Contact: Asa Josefsson
asa.josefsson@astrazeneca.com
302-885-4109
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. New 2008 Health Plan Directory Features Year-End 2007 Enrollment Data and 4,600 Key Executives
3. Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21
4. Medicares Drug Program Enrollment Up, Costs Down
5. MedicareCRM(TM) Simplifies Annual Enrollment Period for Medicare Health Plans and Beneficiaries
6. Boosts in Managed Care Enrollment Seen Across The Board
7. Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
8. Blue Cross Stop Smoking Phone Coaching Enrollments Jumped in October
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
11. Medicare Rx Beneficiaries Urged to Review Changes to Their Drug Plans and Compare with Other Plans During Open Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Whippany, New Jersey (PRWEB) , ... February 11, 2016 , ... ... invited to a free CEU seminar titled, “Stroke Management: Time to Act, Time to ... Senior Housing Community in Whippany, N.J. The presenter is Vishal Chedda, president of ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 budget request ... shift more of the cost burden to military beneficiaries. , MOAA’s president, retired ... defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new ... plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the ... recommendations for rhinoplasty surgeons when addressing this vital area. , The upper lateral ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, ... and audits, privacy and security law, and best practices in data breaches for ...
(Date:2/11/2016)... ... 11, 2016 , ... Talix today announced that Clive Fields, ... presenting at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 ... “ Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the engagement of ... Company,s Global Medical Consultant. Dr. Birgerson will provide ... Company,s clinical operations team to help ensure timely ...
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
(Date:2/11/2016)... Inc. (NASDAQ: IONS ) announced today that it will ... a.m. Eastern Time to discuss its 2015 financial results and ... . A webcast replay will be available for a limited ... A webcast replay will be available for a limited time ... listen to the call by dialing 877-443-5662 or access the ...
Breaking Medicine Technology: